FibroBiologics, Inc. Common Stock (FBLG)vsModerna Inc (MRNA)
FBLG
FibroBiologics, Inc. Common Stock
$0.90
-2.56%
HEALTHCARE · Cap: $6.57M
MRNA
Moderna Inc
$215.27
-3.63%
HEALTHCARE · Cap: $101.49B
Smart Verdict
WallStSmart Research — data-driven comparison
FBLG leads profitability with a 0.0% profit margin vs -110.5%. MRNA earns a higher WallStSmart Score of 31/100 (F).
FBLG
Avoid25
out of 100
Grade: F
MRNA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FBLG.
Margin of Safety
+73.1%
Fair Value
$150.76
Current Price
$215.27
$64.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Revenue surging 29.2% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 12.7x book value
Weak financial health signals
ROE of -40.8% — below average capital efficiency
Earnings declined 85.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : FBLG
The strongest argument for FBLG centers on Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Revenue Growth. Revenue growth of 29.2% demonstrates continued momentum.
Bear Case : FBLG
The primary concerns for FBLG are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
FBLG profiles as a value stock while MRNA is a growth play — different risk/reward profiles.
FBLG carries more volatility with a beta of 1.84 — expect wider price swings.
MRNA is growing revenue faster at 29.2% — sustainability is the question.
FBLG generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (31/100 vs 25/100) and 29.2% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
FibroBiologics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology, specifically targeting degenerative diseases and spinal disorders. The company's robust intellectual property portfolio and commitment to clinical excellence position it favorably within the rapidly evolving cellular therapy market. By fostering strategic partnerships and enhancing research initiatives, FibroBiologics aims to transform patient care and improve clinical outcomes with its cutting-edge therapeutic solutions.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?